Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | $0.0 | $0.0 | ($872.4M) | $1,887.9M | ($54.1M) | $4,231.6M | $2,018.1M | $4,185.1M | $2,987.8M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Royalty Pharma plc's last 12-month Free Cash Flow is $1,801.5M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Royalty Pharma plc's Free Cash Flow growth was 28.6%. The average annual Free Cash Flow growth rates for Royalty Pharma plc have been (18.5%) over the past three years, 8.6% over the past five years.
Over the last year, Royalty Pharma plc's Free Cash Flow growth was 28.6%, which is higher than industry growth of (0.1%). It indicates that Royalty Pharma plc's Free Cash Flow growth is Good.